Denali Therapeutics Inc.
Denali Therapeutics Inc. (DNLI) Revenue
Annual & quarterly revenue history · segment & region breakdown
DNLI · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsDenali Therapeutics Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2015 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | -$0.33B | -100.00% |
| 2023-12-31 | $0.33B | +$0.22B | +204.74% |
| 2022-12-31 | $0.11B | +$0.06B | +122.90% |
| 2021-12-31 | $0.05B | -$0.29B | -85.50% |
| 2020-12-31 | $0.34B | +$0.31B | +1158.19% |
| 2019-12-31 | $0.03B | -$0.10B | -79.34% |
| 2018-12-31 | $0.13B | +$0.13B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare DNLI revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Denali Therapeutics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Denali Therapeutics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Denali Therapeutics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
DNLI revenue · 4 questionsDNLI's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Denali Therapeutics Inc. SEC filings · GAAP · Denali Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026